Artiva Biotherapeutics
ARTV
72 hedge funds and large institutions have $392M invested in Artiva Biotherapeutics in 2026 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 25 increasing their positions, 2 reducing their positions, and 7 closing their positions.
1,150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 2
457% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 7
261% more capital invested
Capital invested by funds: $108M → $392M (+$283M)
95.24% more ownership
Funds ownership: 68.11% → 163.35% (+95%)
80% more funds holding
Funds holding: 40 → 72 (+32)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$73.8M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$23.7M |
| 3 |
Blackstone Inc
New York
|
+$21.9M |
| 4 |
CP
Caligan Partners
New York
|
+$15.8M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$3.42M |
| 2 |
Millennium Management
New York
|
-$794K |
| 3 |
Two Sigma Investments
New York
|
-$332K |
| 4 |
Jane Street
New York
|
-$254K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$198K |
ARTV Hedge Fund Activity: Q2 2026 in Review
72 of the 8,332 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q2 2026, worth a combined $392M — up 261% from $108M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ARTV positions and 7 closed out — a net gain of 32 holders — while 25 added to existing stakes and 2 trimmed.
The largest buyer was RA Capital Management, adding an estimated $73.8M. The largest seller was venBio Partners, exiting entirely with an estimated $3.42M sold.
- 72 institutional investors held Artiva Biotherapeutics (ARTV) as of Q2 2026, up from 40 in Q1 2026.
- Funds reported $392M of Artiva Biotherapeutics stock for Q2 2026, up 261% quarter-over-quarter.
- 39 funds opened new Artiva Biotherapeutics positions in Q2 2026 and 7 closed out, a net change of +32 holders.
- The largest Artiva Biotherapeutics buyer in Q2 2026 was RA Capital Management, an estimated $73.8M added.
- The largest Artiva Biotherapeutics seller in Q2 2026 was venBio Partners, an estimated $3.42M sold.
Based on aggregated 13F filings for Q2 2026.